Next-Gen Oncology Insights in a Secure Unified Platform

We deliver personalized patient-specific therapy recommendations powered by the latest artificial intelligence research

Get started

Book a demo

OUR PLATFORM

We empower clinicians with access to the world's most-powerful AI technologies

Seamless Integration

We integrate with hospital systems enabling interoperability across labs and data consolidation.

Real-time Therapy Simulations

Powered by predictive modeling and comparative analytics, clinicians can use our platform to validate preclinical findings.

Interactive visualizations

Collaborative environments

Multi-format report generation

Personalized Insights

Our models, tailored for precision medicine, provide patient-unique recommendations.

Secure by Default

All data stored in our platform is encrypted by design, which helps us ensure GDPR and HIPAA compliance.

Clinical Partnerships

We are open to collaborate with medical institutions of any kind, regardless of size, purpose, or specialty.

Soon to be announced

Continuous Improvement

Our AI continuously evolves over time with validated clinical data to enhance the accuracy of its predictions.

TESTIMONIALS

Hear directly from our early-adopters

The vision behind TactusVita is incredibly promising. I see how their approach to combining advanced analytics and real-time decision-making could create a transformative impact in the field of precision medicine.

Tomislav Dragovich PhD, MD

Baptist MD Medical Center

Aleksandar Tripkovic

AstraZeneca

A company with the potential to accelerate clinical trials and refine therapy strategies. This is the kind of innovation the pharmaceutical industry needs in order to deliver precision treatments more effectively to patients worldwide.

TactusVita's platform is set to revolutionize precision medicine. Its integration of advanced single-cell analysis with AI-powered insights stands to be a game-changer, enabling groundbreaking research and more personalized care for patients. When I first heard about this idea, I immediately asked Stefan, “When can we start using this?”